NASDAQ:BIVV

Bioverativ Inc., a biotechnology company, focuses on the research, discovery, development, and commercialization of therapies for the treatment of hemophilia and other blood disorders in the United States, Japan, and internationally. The company offers ELOCTATE, an antihemophilic factor Fc fusion protein; and ALPROLIX, a coagulation factor IX Fc fusion protein for the treatment of hemophilia A and B. It is also developing BIVV001, a preclinical program of the combination of factor VIII-Fc fusion protein for the treatment of hemophilia A; BIVV002, a preclinical program for a recombinant factor IX replacement product for the treatment of patients with hemophilia B; and Bi-Specific antibody program, a preclinical program to develop a non-factor bi-specific antibody for the treatment of patients with hemophilia A, as well as gene therapy program, a preclinical program to develop gene therapies for hemophilia A and B. Bioverativ has collaboration with Swedish Orphan Biovitrum AB (publ) to develop and commercialize ELOCTATE and ALPROLIX worldwide; and a research collaboration agreement with Bicycle Therapeutics Ltd. for the discovery, development, and commercialization of therapies for haemophilia and sickle cell diseases. Bioverativ Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts. As of March 7, 2018, Bioverativ Inc. operates as a subsidiary of Sanofi.